Compile Data Set for Download or QSAR
maximum 50k data
Found 214 with Last Name = 'yamazaki' and Initial = 'y'
TargetTyrosinase(Mus musculus (Mouse))
National Institute Of Advanced Industrial Science And Technology

Curated by ChEMBL
LigandPNGBDBM50414514(PROTOCATECHUAMIDE)
Affinity DataKi:  3.70E+3nMAssay Description:Apparent noncompetitive inhibition of catecholase activity of tyrosinase in mouse B16 cells by Lineweaver-Burke plot analysisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosinase(Mus musculus (Mouse))
National Institute Of Advanced Industrial Science And Technology

Curated by ChEMBL
LigandPNGBDBM50296245(3,4-Dihydroxy-N-[2-(5-hydroxyindol-3-yl)ethyl]benz...)
Affinity DataKi:  6.40E+4nMAssay Description:Apparent noncompetitive inhibition of catecholase activity of tyrosinase in mouse B16 cells by Lineweaver-Burke plot analysisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosinase(Mus musculus (Mouse))
National Institute Of Advanced Industrial Science And Technology

Curated by ChEMBL
LigandPNGBDBM29612(CHEMBL33103 | CVD-0001578 | JOH-MSK-a63bdd1d-4 | N...)
Affinity DataKi:  2.40E+5nMAssay Description:Apparent noncompetitive inhibition of catecholase activity of tyrosinase in mouse B16 cells by Lineweaver-Burke plot analysisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331838((R)-7-[4-(2-ethoxycarbonyl-2-hydroxyethyl)oxy-2-me...)
Affinity DataIC50: <1nMAssay Description:o evaluate the action of the present compounds as a GR agonist, IL-6 production inhibitory action in human corneal epithelial cell line after LPS sti...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM414420((R)-7-[4-(2-ethoxycarbonyl-2-hydroxyethyl)oxy-2-me...)
Affinity DataIC50: <1nMAssay Description:1) The subcultured HCE-T was recovered and the cells were seeded at 2.0×104 cells/0.1 mL/well in a 96-well flat bottom culture plate.2) After culturi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527568(US11186588, Example 26)
Affinity DataIC50:  12.3nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331841((S)-7-[4-(3-cyano-2-hydroxypropyl)oxy-2-methoxyphe...)
Affinity DataIC50:  13nMAssay Description:1) The subcultured HCE-T was recovered and the cells were seeded at 2.0×104 cells/0.1 mL/well in a 96-well flat bottom culture plate.2) After culturi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331841((S)-7-[4-(3-cyano-2-hydroxypropyl)oxy-2-methoxyphe...)
Affinity DataIC50:  13nMAssay Description:o evaluate the action of the present compounds as a GR agonist, IL-6 production inhibitory action in human corneal epithelial cell line after LPS sti...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331840((R)-7-[4-(3-cyano-2-hydroxypropyl)oxy-2-methoxyphe...)
Affinity DataIC50:  14nMAssay Description:1) The subcultured HCE-T was recovered and the cells were seeded at 2.0×104 cells/0.1 mL/well in a 96-well flat bottom culture plate.2) After culturi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331840((R)-7-[4-(3-cyano-2-hydroxypropyl)oxy-2-methoxyphe...)
Affinity DataIC50:  14nMAssay Description:o evaluate the action of the present compounds as a GR agonist, IL-6 production inhibitory action in human corneal epithelial cell line after LPS sti...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331839((S)-7-[4-(2,4-dihydroxybutyl)oxy-2-methoxyphenyl]-...)
Affinity DataIC50:  15nMAssay Description:o evaluate the action of the present compounds as a GR agonist, IL-6 production inhibitory action in human corneal epithelial cell line after LPS sti...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331839((S)-7-[4-(2,4-dihydroxybutyl)oxy-2-methoxyphenyl]-...)
Affinity DataIC50:  15nMAssay Description:1) The subcultured HCE-T was recovered and the cells were seeded at 2.0×104 cells/0.1 mL/well in a 96-well flat bottom culture plate.2) After culturi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527554(US11186588, Example 9)
Affinity DataIC50:  17.6nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527550(US11186588, Example 5)
Affinity DataIC50:  27.5nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527563(US11186588, Example 21 | US11186588, Example 22)
Affinity DataIC50:  30.3nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527557(US11186588, Example 12)
Affinity DataIC50:  32.1nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331836((S)-8-(5-fluoro-2-methylphenoxymethyl)-7-[4-(2-hyd...)
Affinity DataIC50:  33nMAssay Description:o evaluate the action of the present compounds as a GR agonist, IL-6 production inhibitory action in human corneal epithelial cell line after LPS sti...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331836((S)-8-(5-fluoro-2-methylphenoxymethyl)-7-[4-(2-hyd...)
Affinity DataIC50:  33nMAssay Description:1) The subcultured HCE-T was recovered and the cells were seeded at 2.0×104 cells/0.1 mL/well in a 96-well flat bottom culture plate.2) After culturi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527563(US11186588, Example 21 | US11186588, Example 22)
Affinity DataIC50:  33.6nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331837((R)-8-(5-fluoro-2-methylphenoxymethyl)-7-[4-(2-hyd...)
Affinity DataIC50:  34nMAssay Description:o evaluate the action of the present compounds as a GR agonist, IL-6 production inhibitory action in human corneal epithelial cell line after LPS sti...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331837((R)-8-(5-fluoro-2-methylphenoxymethyl)-7-[4-(2-hyd...)
Affinity DataIC50:  34nMAssay Description:1) The subcultured HCE-T was recovered and the cells were seeded at 2.0×104 cells/0.1 mL/well in a 96-well flat bottom culture plate.2) After culturi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527616(US11186588, Example 92)
Affinity DataIC50:  34.2nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527608(US11186588, Example 81)
Affinity DataIC50:  47.2nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527567(US11186588, Example 25)
Affinity DataIC50:  50.3nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527549(US11186588, Example 3)
Affinity DataIC50:  51.9nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527560(US11186588, Example 16)
Affinity DataIC50:  77.5nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331842(7-[4-(3-t-butoxycarbonyl-2-hydroxypropyl)oxy-2-met...)
Affinity DataIC50:  83nMAssay Description:o evaluate the action of the present compounds as a GR agonist, IL-6 production inhibitory action in human corneal epithelial cell line after LPS sti...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331842(7-[4-(3-t-butoxycarbonyl-2-hydroxypropyl)oxy-2-met...)
Affinity DataIC50:  83nMAssay Description:1) The subcultured HCE-T was recovered and the cells were seeded at 2.0×104 cells/0.1 mL/well in a 96-well flat bottom culture plate.2) After culturi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527551(US11186588, Example 6)
Affinity DataIC50:  86.4nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527572(US11186588, Example 33)
Affinity DataIC50:  87.2nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331844(8-(5-fluoro-2-methylphenoxymethyl)-7-(5-hydroxy-2-...)
Affinity DataIC50:  93nMAssay Description:1) The subcultured HCE-T was recovered and the cells were seeded at 2.0×104 cells/0.1 mL/well in a 96-well flat bottom culture plate.2) After culturi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331844(8-(5-fluoro-2-methylphenoxymethyl)-7-(5-hydroxy-2-...)
Affinity DataIC50:  93nMAssay Description:o evaluate the action of the present compounds as a GR agonist, IL-6 production inhibitory action in human corneal epithelial cell line after LPS sti...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527610(US11186588, Example 83 | US11186588, Example 86)
Affinity DataIC50:  95.3nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527617(N-(4-(2,3,9-trimethyl-6H-thieno[2,3-e][1,2,4]triaz...)
Affinity DataIC50:  96nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527553(US11186588, Example 8)
Affinity DataIC50:  104nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527575(US11186588, Example 38)
Affinity DataIC50:  106nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331843(8-(5-fluoro-2-methylphenoxymethyl)-7-(5-hydroxymet...)
Affinity DataIC50:  123nMAssay Description:1) The subcultured HCE-T was recovered and the cells were seeded at 2.0×104 cells/0.1 mL/well in a 96-well flat bottom culture plate.2) After culturi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-6(Homo sapiens (Human))
Santen Pharmaceutical

US Patent
LigandPNGBDBM331843(8-(5-fluoro-2-methylphenoxymethyl)-7-(5-hydroxymet...)
Affinity DataIC50:  123nMAssay Description:o evaluate the action of the present compounds as a GR agonist, IL-6 production inhibitory action in human corneal epithelial cell line after LPS sti...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527609(US11186588, Example 82)
Affinity DataIC50:  135nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527561(US11186588, Example 18)
Affinity DataIC50:  144nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527571(US11186588, Example 31)
Affinity DataIC50:  150nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527565(US11186588, Example 23)
Affinity DataIC50:  158nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527555(US11186588, Example 10)
Affinity DataIC50:  192nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527585(US11186588, Example 49)
Affinity DataIC50:  197nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527558(US11186588, Example 13)
Affinity DataIC50:  233nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527601(US11186588, Example 73)
Affinity DataIC50:  246nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527587(US11186588, Example 51)
Affinity DataIC50:  265nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527570(US11186588, Example 29)
Affinity DataIC50:  265nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527559(US11186588, Example 14)
Affinity DataIC50:  276nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNuclear factor NF-kappa-B p105 subunit(Homo sapiens (Human))
Ayumi Pharmaceutical

US Patent
LigandPNGBDBM527618(US11186588, Example 103 | US11186588, Example 99)
Affinity DataIC50:  289nMAssay Description:A549/NF-κB-luc cells (available from Panomics, Cat No. LR0051) were prepared at 375,000 cells/mL in the culture medium. The 375,000 cells/mL A54...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 214 total ) | Next | Last >>
Jump to: